SIREN : 524952132
HOLDING AXIDOC is a French company founded 15 years ago, specialized in the sector Activités des sociétés holding. Based in TOULOUSE (31400), this company of category PME shows in 2024 a revenue of 1.9 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 905 886 € | 1 796 401 € | 1 785 851 € | 1 617 401 € | 1 219 157 € | 1 166 776 € | 1 134 358 € | 1 174 145 € | N/C |
| Net income | 107 172 € | 76 972 € | 2 582 864 € | 275 175 € | 309 207 € | 121 592 € | 121 690 € | 97 545 € | 69 390 € |
| EBITDA | 124 035 € | 50 137 € | 191 681 € | 281 192 € | 133 648 € | 120 909 € | 450 990 € | 112 361 € | -614 865 € |
| Net margin | 5.6% | 4.3% | 144.6% | 17.0% | 25.4% | 10.4% | 10.7% | 8.3% | N/C |
In 2024, HOLDING AXIDOC achieves revenue of 1.9 M€. Over the period 2017-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +7.2%. Vs 2023: +6%. After deducting consumption (-2 k€), gross margin stands at 1.9 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 124 k€, representing 6.5% of revenue. Positive scissor effect: EBITDA margin improves by +3.7 pts, sign of improved operational efficiency. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 107 k€, i.e. 5.6% of revenue. This profit can be retained or distributed to shareholders.
1 905 886 €
1 907 514 €
124 035 €
94 190 €
107 172 €
6.5%
The debt ratio (= Financial debt / Equity x 100) stands at 47%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 60%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 8.2 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 6.7% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.
46.781%
59.717%
6.738%
8.247
37.3%
In 2024, the debt ratio of HOLDING AXIDOC (46.78) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of HOLDING AXIDOC (59.7%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of HOLDING AXIDOC (8.25) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 559.70. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 1.4x. Coverage is limited: any activity downturn would jeopardize interest payments.
559.704
1.375
In 2024, the liquidity ratio of HOLDING AXIDOC (559.70) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of HOLDING AXIDOC (1.4x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 71 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 26 days. The gap of 45 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Overall, WCR represents 416 days of revenue, i.e. 2.2 M€ to permanently finance.
2 202 499 €
71 j
26 j
0 j
416 j
Based on 54 transactions of similar company sales
in 2024,
the value of HOLDING AXIDOC is estimated at
667 840 €
(range 280 157€ - 1 077 110€).
With an EBITDA of 124 035€, the sector multiple of 4.8x is applied.
The price/revenue ratio is 0.59x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 54 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare HOLDING AXIDOC with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of HOLDING AXIDOC in 2024 is 1.9 M€.
Yes, HOLDING AXIDOC generated a net profit of 107 k€ in 2024.
The headquarters of HOLDING AXIDOC is located in TOULOUSE (31400), in the department Haute-Garonne.
The tax return of HOLDING AXIDOC is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
HOLDING AXIDOC operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.